Company Overview and News

 
URA / Global X Funds 485BPOS

2018-04-20 sec.gov
Document As filed with the U.S. Securities and Exchange Commission on April 20, 2018
Upvote Downvote

 
The Future Of Transportation Is Autonomous And Electric

2018-04-17 seekingalpha
On April 17th, the Global X Autonomous & Electric Vehicles ETF (NASDAQ:DRIV) began trading. DRIV seeks to invest in companies involved in the development of autonomous vehicle technology, electric vehicles (EVs), and EV components and materials. This includes companies involved in the development of autonomous vehicle software and hardware, as well as companies that produce EVs, EV components such as lithium batteries, and critical EV materials such as lithium and cobalt.
Upvote Downvote

 
URA / Global X Funds 497K

2018-04-17 sec.gov
Document
Upvote Downvote

 
URA / Global X Funds 485BXT

2018-04-12 sec.gov
Document As filed with the U.S. Securities and Exchange Commission
Upvote Downvote

 
The FERC Ruling And Its Impact On MLPs

2018-04-11 seekingalpha
Since 2005, the Federal Energy Regulatory Commission (FERC) allowed master limited partnerships ((MLPs)) to factor in the recovery of an income tax allowance (ITA) in setting their tariff rates for regulated cost-of-service pipelines.1 On March 15, 2018, FERC announced a new rule that will prevent MLPs from recovering this ITA.1
Upvote Downvote

 
URA / Global X Funds null

2018-04-11 sec.gov
begin 644 8A_Cert_DRIV.pdf M)5!$1BTQ+C4-)>+CS],-"C8Y(# @;V)J#3P\+TQI;F5A8F)D M8!!@8&)@8)H$(AFG@,D<$,FQ%41RI8%%E$ D=R2(]+D'%LD&D7E,8+W:0)+1 M<2E87 -$RKJ 2$4^(/E_X7(&)J M5T B0'F:D_\9&%>\!P@P $R"#3L-"F5N M9'-T
Upvote Downvote

 
URA / Global X Funds AUTO-GENERATED PAPER DOCUMENT

2018-04-11 sec.gov
This document was generated as part of a paper submission. Please reference the Document Control Number 17000789 for access to the original document.
Upvote Downvote

4
URA / Global X Funds 8-A12B

2018-04-10 sec.gov
Document UNITED STATES
Upvote Downvote

2
URA / Global X Funds 497

2018-04-06 sec.gov
Document
Upvote Downvote

1
URA / Global X Funds 485BPOS

2018-04-05 sec.gov
Document As filed with the U.S. Securities and Exchange Commission
Upvote Downvote

1
URA / Global X Funds 485BXT

2018-04-05 sec.gov
Document As filed with the U.S. Securities and Exchange Commission
Upvote Downvote

 
URA / Global X Funds N-Q (Quarterly Schedule of Portfolio Holdings)

2018-03-29 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

1
URA / Global X Funds AUTO-GENERATED PAPER DOCUMENT

2018-03-28 sec.gov
This document was generated as part of a paper submission. Please reference the Document Control Number 17000791 for access to the original document.
Upvote Downvote

2
URA / Global X Funds AUTO-GENERATED PAPER DOCUMENT

2018-03-28 sec.gov
This document was generated as part of a paper submission. Please reference the Document Control Number 17000794 for access to the original document.
Upvote Downvote

 
URA / Global X Funds 497

2018-03-28 sec.gov
Document Global X Uranium ETF (the “Fund”)
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 37954Y848